Drugs / Ocalivumab
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06758037 | Jan 2025 → Dec 2026 expected | diffuse large B-cell lymphoma | First Affiliated Hospital of Ningbo University | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ocalivumab | “For MCD/BN2/TP53: Ocalivumab 150mg qd” NCT06758037 ↗ |